Graft-versus-host disease is a life-threatening problem for many bone-marrow transplant recipients.
New therapies are urgently needed to control the condition.
This study identifies a molecule that controls severity of the disease; blocking the molecule could help control the condition.
COLUMBUS, Ohio – Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
The study, led by researchers with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), used an animal model and tissues from human patients to show that high levels, or over-expression, of a molecule called microRNA-155 (miR-155) controls the severity of acute graft-versus-host disease (GVHD).
Reducing or blocking miR-155 expression, on the other hand, decreased acute GVHD severity and increased survival, a finding that suggests a new strategy for treating the condition.
Acute GVHD occurs in 35 to 45 percent of leukemia patients overall who receive a blood stem-cell transplant from another person, a procedure called allogeneic stem-cell transplantation. Severe acute GVHD has a poor prognosis: about 25 percent of patients survive grade III GVHD and about 5 percent survive grade IV disease.
The findings are published in the journal Blood.
"Currently, acute GVHD is treated with high doses of steroids, which further increase the patient's already high risk for infections, and they block the ability of the donor immune cells to fight the leukemia," says principal investigator and hematologist Dr. Ramiro Garzon, assistant professor of internal medicine and a leukemia specialist.
"What is needed is a way to block acute GVHD without inhibiting the ability of transplanted cells to fight leukemia, and these findings suggest how that might be done," Garzon says.
GVHD arises when immune cells from the donor attack the healthy tissue of the recipient. For this study, Garzon and his colleagues used an animal model of GVHD to learn if miR-155 played a role in the disease. Donor animals were engineered to either over-express or under-express miR-155 in their T cells, the main type of immune cell involved in GVHD.
The researchers first learned that donor T cells removed from recipient animals with GVHD had levels miR-155 that were up to 6.5-fold greater than in controls. Additional experiments showed the following:
When recipient animals are given T cells that are deficient in miR-155, GVHD severity is much less and overall survival is significantly greater.
When recipient animals are given T cells that over-express miR-155, GVHD develops rapidly and survival is short.
Blocking miR-155 in donor cells decreases the severity of clinical GVHD, increases survival and does not diminish the cells' ability to destroy leukemia cells.
Finally, Garzon and his colleagues examined five large-bowel biopsies of GVHD patients, and inflammatory T cells from all five showed high levels of miR-155. "This suggests that the relationship between miR-155 and graft-versus-host disease is relevant in humans, also," Garzon says.
Funding from the National Cancer Institute and a Pelotonia Fellowship Award supported this research.
Other researchers involved in this study were Parvathi Rangananthan, Catherine E.A. Heaphy, Stefan Costinean, Nicole Stauffer, Caroline Na, Ramasamy Santhanam, Charlene Mao, Sukhinder Sandhu, Arwa Shana'ah, Gerard J. Nuovo, John C. Byrd, Michael Caligiuri, Danilo Perrotti, Greg Hadley, Guido Marcucci, Steven M. Devine and Carlo M. Croce of Ohio State University; Mehdi Hamadani of West Virginia University; Patricia A. Taylor and Bruce R. Blazar of the University of Minnesota; Gang He of the University of Manitoba, Canada; Sussana Obad, Oliver Broom and Sakari Kauppinen of Santaris Pharma, Hørsholm, Denmark.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 40 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by
U.S.News & World Report.
A high quality JPEG of Ramiro Garzon, MD, is available here.
Contact: Darrell E. Ward, Medical Center Public Affairs and Media Relations,
614-293-3737, or Darrell.Ward@osumc.edu